Global Rare Hemophilia Factors Market Size Study & Forecast, by Type (Factor I, Factor II, Factor V, Factor VII, Factor X, Factor XI, Factor XIII), by Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate, Others) and Regional Analysis, 202

Global Rare Hemophilia Factors Market Size Study & Forecast, by Type (Factor I, Factor II, Factor V, Factor VII, Factor X, Factor XI, Factor XIII), by Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate, Others) and Regional Analysis, 2023-2030

Global Rare Hemophilia Factors Market is valued at approximately USD 294.7 million in 2022 and is anticipated to grow with a healthy growth rate of more than 6.9% over the forecast period 2023-2030. Hemophilia is a genetic disorder that affects blood clotting, caused by a deficiency in clotting factors such as Factor VII, Factor IX, and Factor XIII. The market for rare hemophilia factors is growing due to advancements in early and accurate diagnosis, which helps healthcare providers identify patients with specific types of hemophilia and determine the best treatment options. Healthcare professionals and patients are becoming more aware of these advancements, and new treatment techniques that are being developed.

Also, the rising adoption and approval of new treatment techniques are driving the market. As per the article published by the National Institute of Health in 2021 under the title ‘Recent Advances in the Treatment of Hemophilia: A Review’, with the introduction of a bi-specific monoclonal antibody, a new era of prevention and treatment of bleeding started that clones the effects of Factors VIII in the tenase complex. The ongoing research to improve the efficacy and safety of rare hemophilia factor products is creating an opportunity for the market. The use of digital health technologies such as telemedicine and mobile health apps can be used to improve patients’ self-management. However, the high cost of treatments remains a significant challenge, especially in low-income countries. Also, the reimbursement policies have a significant impact on access to treatment.

The key regions considered for the Global Rare Hemophilic Factors Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 due to the government’s initiatives to increase diagnosis rates and reduce treatment costs, research activities, and therapeutic advances in hemophilia. The National Organization for Rare Disorders (NORD) offers various research grants to study rare diseases. Furthermore, recent approvals by the U.S. FDA for some coagulation factor concentrates have assisted in boosting the regional market. Asia Pacific is expected to grow significantly over the forecast period, due to the rising incidence of autosomal recessive disorders in countries such as India, Pakistan, and China. According to a study titled ""Epidemiological study of consanguineous marriage and its effects"" published in the International Journal of Community Medicine and Public Health, the Middle East, Africa, and South Asia have a high prevalence of consanguineous marriages, estimated to be around 20.0% to 50.0% of all marriages.


Major market player included in this report are:
Novo Nordisk A/S
Biogen Inc.
Bayer Healthcare
Pfizer, Inc.
Shire Plc
Sanofi S.A
CSL Behring
Bio Products Laboratory Ltd.
Eli Lilly and Company
GSK Plc

Recent Developments in the Market:
 In February 2022, Biocon acquired Viatris' biosimilar portfolio, which resulted in strengthening its product offerings and revenue generation.
 In May 2022, F. Hoffmann-La Roche Ltd., a Swedish multinational healthcare company, extended its partnership with the World Federation of Hemophilia (WFH) until 2028 to provide access to hemophilia treatments. The company offer its prophylactic treatment for hemophilia A to the WFH's Humanitarian Aid Program, that distribute it to people in areas with limited access to quality hemophilia treatments.
 In May 2022, Takeda Pharmaceutical Co Ltd launched Adynovate, an innovative extended half-life recombinant Factor VIII treatment in India for hemophilia A patients.
 In June 2022, the United States Food and Drug Administration granted breakthrough therapy designation to 'efanesoctocog alfa' for hemophilia A. This therapy is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA, based on data from the XTEND-1 Phase 3 study, which demonstrated clinically meaningful prevention of bleeds and superiority in the prevention of bleeding episodes compared to prior prophylaxis factor treatment.
 In August 2022, The Food and Drug Administration (FDA) announced the approval of Rebinyn, a coagulation factor IX recombinant, received approval for routine prophylaxis to reduce the frequency of bleeding episodes in children and adults with hemophilia B.

Global Rare Hemophilic Factors Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Type, Treatment, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Type offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Factor I
Factor II
Factor V
Factor VII
Factor X
Factor XI
Factor XIII

By Treatment:
Factor Concentrates
Fresh Frozen Plasma
Cryoprecipitate
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Novo Nordisk A/S
Biogen Inc.
Bayer Healthcare
Pfizer, Inc.
Shire Plc
Sanofi S.A
CSL Behring
Bio Products Laboratory Ltd.
Eli Lilly and Company
GSK Plc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.